エリスロポエチン薬品の世界市場2021年-2028年:製品種類別(エポエチン-アルファ、エポエチン-ベータ、ダルベポエチン-アルファ、その他)、用途別

◆英語タイトル:Erythropoietin Drugs Market by Product Type (Epoetin-Alfa, Epoetin-Beta, and Darbepoetin-Alfa, Others) and Application (Hematology, Kidney Disorder, Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2021–2028
◆商品コード:AMR21JU068
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2021年5月28日
◆ページ数:165
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,168 ⇒換算¥678,480見積依頼/購入/質問フォーム
5 UserUSD6,929 ⇒換算¥762,190見積依頼/購入/質問フォーム
Enterprise UserUSD9,663 ⇒換算¥1,062,930見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、エリスロポエチン薬品の世界市場について調査し、イントロダクション、エグゼクティブサマリー、市場概要、製品別(エポエチンアルファ、エポエチンベータ、ダルベポエチン-アルファ、その他)分析、用途別(血液、腎障害(ESRD・透析)、がん、その他)分析、地域別分析、企業情報などを掲載しています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・エリスロポエチン薬品の世界市場規模:製品別(エポエチンアルファ、エポエチンベータ、ダルベポエチン-アルファ、その他)
・エリスロポエチン薬品の世界市場規模:用途別(血液、腎障害(ESRD・透析)、がん、その他)
・エリスロポエチン薬品の世界市場規模:地域別
・企業情報
【レポートの概要】

The erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected to reach $ 14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin-alfa, epoetin-beta, darbepoetin-alfa, epoetin-omega, and epoetin-delta.

Rise in number of patients suffering from anemic conditions induced due to cancer, HIV and ESRD treatment, favorable reimbursements, and increase in commercialization of EPO biosimilars are the major factors for the market growth. However, side effects such as arterial hypertension, iron deficiency, influenza-like syndrome, and longer treatment period (4-6 weeks) hampers growth of erythropoietin drugs market. Availability of numerous biosimilars has rendered low-cost options for patients, therefore, increased adoption rates for EPO drugs particularly in developing regions, which boosts the market growth. Furthermore, commercialization patterns for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and awareness regarding benefits of EPO therapeutics contribute toward growth of erythropoietin drugs market.
The global erythropoietin drugs market is segmented into product type, application, and region. On the basis of product type, the market is categorized into epoetin-alfa, epoetin-beta, darbepoetin alfa. By application, it is classified into anemia, kidney disorders, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global erythropoietin drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products of erythropoietin used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Type
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin alfa

By Application
• Anemia
• Kidney Disorders
Others

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Amgen Inc.
• Biocon,
• Celltrion, Inc.
• Intas Pharmaceuticals
• Johnson & Johnson
• Hospira Inc.
• Intas Pharmaceuticals
• LG Life Sciences Ltd.
• Roche
• Ranbaxy Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary Research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Clinical trials for EPO drug
3.3.Market share analysis, 2020
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.4.1.2.Growing trends of commercialization for erythropoietin biosimilars
3.4.1.3.Increasing level of awareness about the benefits of EPO therapeutics

3.4.2.Restraints

3.4.2.1.Unaffordability of therapeutics
3.4.2.2.Longer duration of treatments
3.4.2.3.Adverse amount of side effects

3.4.3.Opportunities

3.4.3.1.Commercialization of Darbepoetin alfa biosimilar
3.4.3.2.Achieving Economies of scale across developed region with biosimilar version of EPO

3.5.Impact of Covid-19 on Erythropoietin Drug Market

CHAPTER 4:GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS

4.1.Epoetin-alfa

4.1.1.Key market trends and opportunities
4.1.2.Market size and forecast
4.1.3.Market analysis, by country

4.2.Epoetin-beta

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.Darbepoetin-alfa

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Other

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS

5.1.Hematology

5.1.1.Market size and forecast
5.1.2.Market analysis, by country

5.2.Kidney Disorders (ESRD and Dialysis)

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.Cancer

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.Others

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

CHAPTER 6:GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY

6.1.North America

6.1.1.Key market trends & opportunities
6.1.2.Market size and forecast

6.2.Europe

6.2.1.Key market trends & opportunities
6.2.2.Market size and forecast

6.3.Asia-Pacific

6.3.1.Key market trends & opportunities
6.3.2.Market size and forecast

6.4.LAMEA

6.4.1.Key market trends & opportunities
6.4.2.Market size and forecast

CHAPTER 7:COMPANY PROFILES

7.1.AMGEN INC.

7.1.1.Company overview
7.1.2.Amgen Inc. snapshot
7.1.3.Operating Business Segment
7.1.4.Financial performance

7.2.JOHNSON AND JOHNSON

7.2.1.Company overview
7.2.2.Johnson & Johnson snapshot
7.2.3.Operating Business Segment overview
7.2.4.Financial performance

7.3.ROCHE DIAGNOSTICS

7.3.1.Company overview
7.3.2.Roche Diagnostics snapshot
7.3.3.Operating Business Segment Overview
7.3.4.Financial performance

7.4.HOSPIRA INC.

7.4.1.Company overview
7.4.2.Hospira Inc. snapshot
7.4.3.Operating business segment
7.4.4.Financial performance
7.4.5.Key Strategies move & development

7.5.LG LIFE SCIENCES LTD.

7.5.1.Company overview
7.5.2.LG Life Sciences Ltd. snapshot
7.5.3.Operating Business segment overview
7.5.4.Financial performance

7.6.BIOCON

7.6.1.Company overview
7.6.2.Biocon snapshot
7.6.3.Operating Business Segment Overview
7.6.4.Financial performance
7.6.5.Key Strategies move and development

7.7.INTAS PHARMACEUTICALS

7.7.1.Company overview
7.7.2.Intas Pharmaceuticals snapshot
7.7.3.Operating Business Segment Overview
7.7.4.Financial performance

7.8.TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.8.1.Company overview
7.8.2.Teva Pharmaceutical Industries Ltd. snapshot
7.8.3.Operating business segment overview
7.8.4.Financial performance

7.9.RANBAXY LABORATORIES LTD.

7.9.1.Company overview
7.9.2.Ranbaxy Laboratories Ltd. snapshot
7.9.3.Operating business segment overview
7.9.4.Financial performance

7.10.CELLTRION, INC

7.10.1.Company overview
7.10.2.Celltrion, Inc. snapshot
7.10.3.Financial performance

LIST OF TABLES

TABLE 01.CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
TABLE 02.GLOBAL ERYTHROPOIETIN DRUG MARKET BY PRODUCT TYPES, 2020-2028($MILLION)
TABLE 03.GLOBAL ERYTHROPOIETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 04.GLOBAL ERYTHROPOIETIN BETA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 05.GLOBAL DARBEPOETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 06.GLOBAL OTHER DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 07.GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS, 2020-2028($MILLION)
TABLE 08.GLOBAL HEMATOLOGY APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 09.GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 10.GLOBAL CANCER APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 11.GLOBAL OTHERS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 12.GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2020 – 2020 ($MILLION)
TABLE 13.NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 15.EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 17.ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 18.LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 19.AMGEN INC. SNAPSHOT
TABLE 20.AMGEN INC. OPERATING BUSINESS SEGMENT
TABLE 21.JOHNSON & JOHNSON SNAPSHOT
TABLE 22.JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 23.ROCHE DIAGNOSTICS SNAPSHOT
TABLE 24.ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 25.HOSPIRA INC. SNAPSHOT
TABLE 26.HOSPIRA INC. OPERATING SEGEMENTS
TABLE 27.LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
TABLE 28.LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
TABLE 29.BIOCON SNAPSHOT
TABLE 30.BIOCON OPERATING SEGEMENTS
TABLE 31.INTAS PHARMACEUTICALS SNAPSHOT
TABLE 32.INTAS PHARMACEUTICALS OPERATING SEGEMENTS
TABLE 33.TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
TABLE 34.TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
TABLE 35.RANBAXY LABORATORIES LTD. SNAPSHOT
TABLE 36.CELLTRION, INC. SNAPSHOT

LIST OF FIGURES

FIGURE 01.GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
FIGURE 02.MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2020)
FIGURE 03.FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2020)
FIGURE 04.FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2020)
FIGURE 05.SWOT ANALYSIS OF AMGEN INC.
FIGURE 06.FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2020)
FIGURE 07.FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS(2020)
FIGURE 08.SWOT ANALYSIS OF JOHNSON & JOHNSON
FIGURE 09.FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2020)
FIGURE 10.FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2020)
FIGURE 11.SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIGURE 12.FINANCIAL REVENUE OF HOSPIRA INC. BY GEOGRAPHY (2020)
FIGURE 13.FINANCIAL REVENUE OF HOSPIRA INC. BY BUSINESS UNITS (2020)
FIGURE 14.SWOT ANALYSIS OF HOSPIRA INC.
FIGURE 15.NET REVENUE GENERATION (2011-2020)
FIGURE 16.SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
FIGURE 17.REVENUE GENERATED BY BUSINESS UNITS (2020)
FIGURE 18.SWOT ANALYSIS OF BIOCON
FIGURE 19.SWOT ANALYSIS OF INTAS PHARMACEUTICALS
FIGURE 20.NET REVENUE GENERATION BY GEOGRAPHY (2020)
FIGURE 21.NET REVENUE GENERATION BY BUSINESSES (2020)
FIGURE 22.SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIGURE 23.KEY FINANCIALS OF RANBAXY LABORATORIES LIMITED BY GEOGRAPHY (2014)
FIGURE 24.SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
FIGURE 25.NET PROFIT DURING 2011-2020
FIGURE 26.SWOT ANALYSIS OF CELLTRION, INC.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[エリスロポエチン薬品の世界市場2021年-2028年:製品種類別(エポエチン-アルファ、エポエチン-ベータ、ダルベポエチン-アルファ、その他)、用途別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆